TGA approves new indication for GSK's RSV vaccine

The health election debate mainly concerned bulk billing. New bureaucracies are rarely the solution to anything, and the challenge of faster funded access to new health technologies, particularly when advisory committees with power appear opposed. The complexity of weight-loss therapies presents opportunities.

This publication has and will continue to argue that processes like the HTA review simply cannot deliver the reform people expect because it's not an enabling policy framework. It will deliver targeted adjustments to the access barrier. Is that what stakeholders want?

The release of the Trump administration's terms of reference for its trade negotiations with India has revealed no significant interest in pharmaceutical issues, despite the country's standing as one of the worst offenders on intellectual property protection.

Roche has announced it will invest US$50 billion in the US over the next few years in a move that appears aimed at mitigating the risk of tariffs.

Pfizer has launched Part of the Story to mark World Book Day today, advocating a global campaign to help reimagine traditional cancer narratives and keep pace with science.

The US biopharmaceutical industry will welcome the Trump administration's move to scrap the so-called 'pill penalty' introduced as part of the Biden administration's Inflation Reduction Act but will be less supportive of other proposed measures.

Researchers at the University of Queensland are attempting to create a vaccine in just 150 days to demonstrate their ability to respond to a pandemic as part of a program backed by the Coalition for Epidemic Preparedness Innovations.

New research from the Sydney-based Centenary Institute has found that switching off a specific protein in liver cells could help prevent the early development of liver cancer.

Investors have shrugged off concerns over US President Donald Trump's planned tariffs on pharmaceutical imports with CSL's share price closing up over 2 per cent yesterday.

Ask this question - if Australian decision-makers can disregard the human impact of delays in reimbursed access to health technologies, why should they be excused from considering the broader consequences?

“The growth in our Medical Affairs team is testament to the strength of what our pipeline is delivering in Australia now and what we can see on the horizon as a priority market for the company,” said Nirelle Tolstoshev, the general manager of Astellas Pharma Australia.

UCB has announced that the TGA has approved BIMZELX (bimekizumab) to include the treatment of adults living with moderate to severe hidradenitis suppurativa.

The industry's 'Faustian bargain' on the 'sanctity' of the PBS, the challenge so many have in being clear about the problem, and why Pathology Australia provides an important lesson. Another wrong political message on newborns, why dentists might be worried, positive news on a critical medicines reform, and kudos to a pharmacy chain for promoting flu vaccines.

According to an update from the Pharmaceutical Benefits Advisory Committee, it recently received correspondence from Health Minister Mark Butler requesting its advice "on equitable access to medicines for treatment of obesity in Australia."

“Melanie brings a unique perspective and proven leadership in public health policy, and we are thrilled to welcome her to our Executive Team at such a critical time for the sector,” said Medicines Australia CEO Liz de Somer.

Ann Maccarrone, community engagement and partnerships manager at ViiV Healthcare Australia, said, “We are honoured to support the five recipients of the 2024 PACG program, whose initiatives align with our mission to create meaningful and lasting impact for people living with HIV, and to leave no person living with HIV behind."

The US FDA has announced a plan to replace animal testing in the development of monoclonal antibody therapies and other drugs with 'human-relevant' methods such as advanced computer simulations and human-based lab models.

During the 2022 election campaign, Prime Minister Anthony Albanese and Mr Butler were unequivocal about their commitment to newborns and their parents.

The implementation group should not feel constrained by the recommendations, but it's tough to imagine any Government agreeing to one change without a second. The industry's leadership would understand this and be prepared given the timing.